See What HealthDay Can Do For You
Contact Us

Metformin Recalled Due to Contamination With Carcinogen

No reports of adverse events related to the recall have been reported

pills

TUESDAY, Nov. 3, 2020 (HealthDay News) -- A cancer-causing compound in the drug metformin has resulted in the recall of two lots of the drug.

Kansas City-based Nostrum Laboratories Inc., said Monday that it is voluntarily recalling its metformin HCl extended release tablets, USP 750 mg, according to a notice from the U.S. Food and Drug Administration. No reports of adverse events related to the recall have been reported, the company said.

These tablets are tainted with higher-than-safe levels of the chemical nitrosamine, or NDMA. NDMA is a possible carcinogen, according to the U.S. Environmental Protection Agency.

The affected product is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg lots are under NDC 29033-056-01, lot numbers MET200101 and MET200301, with the expiration date 05/2022. It can be identified as an off-white oblong tablet debossed with "NM7."

More Information

Physician's Briefing
undefined
undefinedundefined